Guoyu Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guoyu Peng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Song Wu
Department of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China
2 shared publications Haiyan Sun
Institute of Urology The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group) China
1 shared publicationHouhong Zhou
Institute of Urology, The Third Affiliated Hospital of Shenzhen University
1 shared publicationHuang Guixiao
The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group)
1 shared publicationJean Thiery
Guangzhou Regenerative medicine and health, Guangdong laboratory
1 shared publicationKai Wu
Institute of Urology The Third Affiliated Hospital of Shenzhen University (Luohu Hospital Group) China
1 shared publication
Latest Publications
- Open Access
- 16 March 2022
- Published by Springer Nature in Research Square
The authors have requested that this preprint be removed from Research Square.
The authors have requested that this preprint be removed from Research Square.
- 16 March 2022
- Published by Springer Nature in Research Square
Open AccessThe authors have requested that this preprint be removed from Research Square.
The authors have requested that this preprint be removed from Research Square.
- Open Access
- 3 August 2021
- Published by Wiley in FEBS Open Bio
- Vol. 11 (9) , 2631-2646
Down‐regulation of Polo‐like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer
Polo‐like kinase 4 (PLK4) has been reported to contribute to tumor growth, invasion, and metastasis. However, the role of PLK4 in human bladder cancer (BC) remains unclear. Here, we demonstrate the regulatory function of PLK4 in human BC progression. PLK4 is overexpressed in BC cell lines and tissues, and its overexpression correlated with poor prognosis. Our transcriptome analysis combined with subsequent functional assays indicated that PLK4 inhibition can suppress BC cell growth and induce cell cycle arrest at G1 phase via activation of the p38/p53/p21 pathway in vitro and in vivo. Overall, our data suggest that PLK4 is a critical regulator of BC cell proliferation, and thus, it may have potential as a novel molecular target for BC treatment.
- 3 August 2021
- Published by Wiley in FEBS Open Bio
- Vol. 11 (9) , 2631-2646
Open AccessDown‐regulation of Polo‐like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer
Polo‐like kinase 4 (PLK4) has been reported to contribute to tumor growth, invasion, and metastasis. However, the role of PLK4 in human bladder cancer (BC) remains unclear. Here, we demonstrate the regulatory function of PLK4 in human BC progression. PLK4 is overexpressed in BC cell lines and tissues, and its overexpression correlated with poor prognosis. Our transcriptome analysis combined with subsequent functional assays indicated that PLK4 inhibition can suppress BC cell growth and induce cell cycle arrest at G1 phase via activation of the p38/p53/p21 pathway in vitro and in vivo. Overall, our data suggest that PLK4 is a critical regulator of BC cell proliferation, and thus, it may have potential as a novel molecular target for BC treatment.